Origo Biopharma
Project Description
Origo Biopharma’s R&D projects are characterized by a high degree of innovation. Currently, the company is focused on the development of TGF-beta inhibitors for the treatment of colon cancer and Crohn’s disease.
Description of the Area of Activity / Technology
Discovery and development of immuno-modulators for the treatment of diseases with an immuno-inflammatory component such as cancer and fibrosis; from the identification and optimization of lead compounds to early preclinical and clinical phase I drug development
Others
Projects
Join us!
Do you want to appear on the platform? If you are part of the biotechnological sector of the Euroregion Galicia – North of Portugal, sign up!